Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785988 | 0.83 | TSHR (0.46) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL6897011 | 0.80 | TSHR (0.41) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL6900414 | 0.78 | PKM (0.41) | TSHRALDH1A1MMP8GAA | |
| SCHEMBL19954643 | 0.77 | TSHR (0.38) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL18924764 | 0.77 | TSHR (0.38) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL14818201 | 0.77 | TSHR (0.38) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL20381909 | 0.76 | TSHR (0.41) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL19018723 | 0.76 | TSHR (0.36) | TSHRSMN1; SMN2MAPK1 | |
| SCHEMBL685935 | 0.74 | PRKCA (0.55) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 | |
| SCHEMBL7945587 | 0.74 | TSHR (0.46) | TSHRALDH1A1PRKCASMN1; SMN2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | TSHR 3059/4885ALDH1A1 760/4885PRKCA 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.